SCHEMBL146483

SCHEMBL146483

CC(C)(C)OC(=O)NC1CNCC1c1cc(F)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.40
NTRK1 P04629 3/20 0.38
EPHX2 P34913 1/20 0.38
HTR2C P28335 1/20 0.38
FPR1 P21462 3/20 0.37
FPR2 P25090 2/20 0.37
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
TAS1R2 Q8TE23 1/20 0.37
KDM1B Q8NB78 1/20 0.37
MAOB P27338 2/20 0.36
KDM4D Q6B0I6 1/20 0.36
MAOA P21397 1/20 0.36
TACR1 P25103 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
RORC P51449 1/20 0.35
F2R P25116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146482 1.00 KDM1A (0.40) KDM1ANTRK1EPHX2HTR2CFPR1
SCHEMBL146484 1.00 KDM1A (0.40) KDM1ANTRK1EPHX2HTR2CFPR1
SCHEMBL145666 0.91 FPR1 (0.44) KDM1AEPHX2HTR2CFPR1FPR2
SCHEMBL145667 0.91 FPR1 (0.44) KDM1AEPHX2HTR2CFPR1FPR2
SCHEMBL145665 0.91 FPR1 (0.44) KDM1AEPHX2HTR2CFPR1FPR2
SCHEMBL461792 0.90 FPR1 (0.46) NTRK1FPR1FPR2
SCHEMBL121024 0.90 FPR1 (0.46) NTRK1FPR1FPR2
SCHEMBL458267 0.90 KDM1A (0.39) KDM1AEPHX2HTR2CFPR1FPR2
SCHEMBL462830 0.87 KDM1A (0.39) KDM1AEPHX2FPR1FPR2MAOB
SCHEMBL170772 0.87 KDM1A (0.39) KDM1AEPHX2FPR1FPR2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059014-A1 Compounds for the Treatment of Metabolic Disorders PROSIDION LIMITED (GB) 2012-03-08 US disclosed
EP-2406256-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2012-01-18 EP disclosed
EP-2406251-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2012-01-18 EP disclosed
WO-2010103335-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-09-16 WO disclosed
WO-2010103334-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059014-A1 Compounds for the Treatment of Metabolic Disorders GPR119, FFAR2, GPBAR1 KDM1A 4195/4885NTRK1 4160/4885EPHX2 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.